Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.74 |
| ▸ | HTR1D | P28221 | 2/20 | 0.74 |
| ▸ | HTR1B | P28222 | 2/20 | 0.74 |
| ▸ | HTR1F | P30939 | 2/20 | 0.74 |
| ▸ | HTR7 | P34969 | 2/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | HTR1E | P28566 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.59 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485865 | 1.00 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL25624178 | 0.91 | HTR6 (0.84) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL24878185 | 0.89 | HTR6 (0.80) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL24878187 | 0.88 | HTR6 (0.78) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL7429747 | 0.87 | HTR6 (0.77) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL29261926 | 0.87 | HTR6 (0.77) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL24878183 | 0.87 | HTR6 (0.77) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL3029516 | 0.86 | HTR6 (0.76) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL3918492 | 0.86 | HTR6 (0.76) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL24877632 | 0.86 | HTR6 (0.75) | HTR6HTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438045-B1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | claimed |
| EP-1438045-A1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-07-21 | — | — | EP | claimed |
| US-20030139424-A1 | Use | BIOVITRUM AB (SE) | 2003-07-24 | — | — | US | claimed |
| WO-2003035061-A1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-01 | — | — | WO | claimed |
| US-6187805-B1 | TREATING CONDITION FOR WHICH SELECTIVE AGONISM OR ANTAGONISM OF 5-HT-6 RECEPTORS IS INDICATED BY ADMINISTERING COMPOUNDS SUCH AS N,N-DIMETHYL 2-(1-(BENZENESULPHONYL)-5-METHOXY-1H-INDOL-3-YL)ETHYLAMINE | MERCK SHARP & DOHME LTD. (GB) | 2001-02-13 | — | — | US | claimed |
| US-20240116870-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2024-04-11 | — | — | US | disclosed |
| US-11866408-B2 | N,N-dimethyltryptamine and related psychedelics and uses thereof | TERRAN BIOSCIENCES INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023283364-A2 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDLICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-1438045-B1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1438045-A1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030139424-A1 | Use | BIOVITRUM AB (SE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003035061-A1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-01 | — | — | WO | disclosed |
| US-6187805-B1 | TREATING CONDITION FOR WHICH SELECTIVE AGONISM OR ANTAGONISM OF 5-HT-6 RECEPTORS IS INDICATED BY ADMINISTERING COMPOUNDS SUCH AS N,N-DIMETHYL 2-(1-(BENZENESULPHONYL)-5-METHOXY-1H-INDOL-3-YL)ETHYLAMINE | MERCK SHARP & DOHME LTD. (GB) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | PNMT, HTR5A, HNMT | HTR6 9/4885HTR1A 6/4885HTR1D 17/4885 |
| US-20240116870-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | PNMT, HTR5A, HNMT | HTR6 9/4885HTR1A 6/4885HTR1D 17/4885 |
| US-11866408-B2 | N,N-dimethyltryptamine and related psychedelics and uses thereof | PNMT, HTR5A, HNMT | HTR6 9/4885HTR1A 6/4885HTR1D 17/4885 |
| US-20030139424-A1 | Use | TPH1, IDO1, TPH2 | HTR6 25/4885HTR1A 32/4885HTR1D 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.